Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Meijing Wu, Denise M. Scholtens, Rohan Savoor, Bin Zhang, Jennifer D. Wu, Craig Horbinski, Rimas V. Lukas, David C. Binder, Derek A. Wainwright*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.

Original languageEnglish (US)
Article number1548242
JournalOncoImmunology
Volume8
Issue number3
DOIs
StatePublished - Mar 4 2019

Keywords

  • IDO
  • Treg
  • brain tumor
  • glioblastoma
  • immunosuppression
  • immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)'. Together they form a unique fingerprint.

  • Cite this